Retatrutide (LY-3437943) is a triple hormone receptor agonist targeting GLP-1, GIP, and GCGR receptors. Clinical trials demonstrate its effectiveness in weight management, with studies showing significant weight reduction in participants.
Our QSC Semaglutide (Retatrutide) is manufactured under strict quality control standards, ensuring high purity and consistent performance for research applications. The product is supplied as lyophilized powder in sterile vials for professional use.
The peptide sequence is: H-Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-α-Me-Leu-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
As a professional manufacturer of QSC Semaglutide and related peptides, we maintain rigorous quality standards throughout production. Our facility operates under pharmaceutical-grade conditions to ensure product integrity.
This product is intended for research purposes only. Not for human consumption or diagnostic use. Proper handling and storage procedures should be followed by qualified researchers.